Summary of Clinical Use

Edrecolomab was developed as a treatment for colon cancer with a Phase 2 study (NCT00002968) being completed. The antibody was approved in Germany (1995) for this indication. The antibody shows little benefit over other therapies for colon cancer, and it was withdrawn from use.

Mechanism Of Action and Pharmacodynamic Effects

Edrecolomab acts by binding to EPCAM on malignant cells (EpCAM), and this attracts immune cells which destroy the malignant cells.